Journal
ONCOTARGET
Volume 7, Issue 34, Pages 54096-54101Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.10262
Keywords
metformin; cancer; metabolism; pharmacokinetics
Categories
Funding
- Ministerio de Ciencia e Innovacion [SAF2012-38914]
- Plan Nacional de I+D+I, Spain
- Instituto de Salud Carlos III [PI15/00285]
- Instituto de Salud Carlos III (Ministerio de Sanidad y Consumo, Fondo de Investigacion Sanitaria) [EC10-125]
- Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) from the Departament d'Economia I Coneixement, Catalonia, Spain [2014 SGR1227, 2014 SGR229]
Ask authors/readers for more resources
How many lives have already been saved by the anti-cancer drug metformin? Inadvertently perhaps, among the millions of type 2 diabetics with occult or known cancers and who have been prescribed metformin since the 1950s, thousands may have benefited from the anticancer properties of this first-line pharmacotherapy. Quo vadis? Now, researchers aim to move metformin from a non-targeted stage of cancer therapy that has been mostly developed retrospectively and empirically into a targeted therapy by following a biological rationale and a predefined mechanism of action. But, who might benefit from metformin? Cui bono? Because metformin is on the leading edge of a new generation of cancer metabolism-targeted therapies, perhaps it is the right time to provide solutions to the challenges that metformin and other onco-biguanides will face in the coming years before becoming incorporated into the therapeutic armamentarium against cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available